CD19-CAR T cell therapy leads to durable clinical response in ~50% of lymphoma patients(Boyle et al, 2024) (Neelapu et al, 2017) (Maude et al, 2018) (Schuster et al, 2017), the factors underpinning resistance to treatment are not well understood. Here, CD19 is linked to lymphoma.